Across the three treatment groups (dulaglutide 1.5 mg, dulaglutide 0.75 mg, and placebo), there were no cases of diabetic ketoacidosis or amputations, and hypotensive episodes/syncope occurred in 0%, 1% and 1%, genital infections in 0%, 0% and 1%, fractures in 1%, 1% and 1%, and gastrointestinal events in 32%, 21% and 17% of patients, respectively [31]
Clinically tested to show visible dark spot reduction in just 4 weeks, Outshine is lightweight, non-comedogenic, and perfect for daily use, even on acne-prone skin
Unmatched Weight Loss Magnitude Retatrutide produced up to 24% total body weight reduction in Phase 2 clinical trials a figure that exceeds every approved GLP-1 agent currently on the market, including tirzepatide (~21%) and semaglutide (~15%)
A typical program lasts approximately four to six weeks